Cannabis sativa is one of the most widely used drugs in the world. In humans, Cannabis sativa is commonly used to alleviate anxiety and pain, among other things, in medical and recreational contexts. In mice, intraperitoneal (i.p.) injections of its primary psychoactive compound, Δ9-tetrahydrocannabinol (THC) produce a characteristic triad of behavioral responses consisting of hypolocomotion, hypothermia, and analgesia. However, injections of THC do not accurately represent how humans typically administer THC, which primarily consists of inhalation and oral consumption. To better model a typical route of administration used by humans, we developed a voluntary oral consumption paradigm in mice whereby THC is formulated in gelatin. Following habituation, mice were given ad libitum access to THC gelatin for 2 hours. We measured the triad behaviors immediately following consumption to determine whether voluntary oral consumption of THC-gelatin using this paradigm induces acute cannabimimetic behaviors. Due to the slow pharmacokinetic activity of orally consumed THC, we measured triad responses immediately, 1 hour, and 2 hours after consumption. To compare our relative THC-gelatin-induced cannabimimetic behaviors to published data, we replicated the triad experiment and demonstrated our ability to obtain dose-dependent triad responses by using i.p. injections. At high concentrations (4mg/15mL) of THC-gelatin, cannabimimetic behavioral responses matched those of mice treated with low-dose (3 mg/kg) of THC i.p. injections. From these initial studies we conclude that development of THC-gelatin formulation triggers characteristic cannabimimetic behavioral effects in mice. These results suggests that classical THC and cannabinoid-dependent behaviors in mice can feasibly be studied with a more translational model (Funded by DA051558). Optimizing an oral administration model of cannabinoids in mice will enable future research on the pharmacology of oral cannabinoid therapeutics.